Abstract
The promising clinical results obtained with engineered T cells, including chimeric antigen receptor (CAR) therapy, call for further advancements to facilitate and broaden their applicability. One potentially beneficial innovation is to exploit new T cell sources that reduce the need for autologous cell manufacturing and enable cell transfer across histocompatibility barriers. Here we review emerging T cell engineering approaches that utilize alternative T cell sources, which include virus-specific or T cell receptor-less allogeneic T cells, expanded lymphoid progenitors, and induced pluripotent stem cell (iPSC)-derived T lymphocytes. The latter offer the prospect for true off-the-shelf, genetically enhanced, histocompatible cell therapy products.
Original language | English |
---|---|
Pages (from-to) | 357-66 |
Number of pages | 10 |
Journal | Stem Cell Research |
Volume | 16 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2 Apr 2015 |
Keywords
- Animals
- Cell Engineering/methods
- Genetic Engineering
- Histocompatibility
- Humans
- Immunologic Deficiency Syndromes/immunology
- Immunotherapy, Adoptive
- Induced Pluripotent Stem Cells/immunology
- Lymphoid Progenitor Cells/immunology
- Receptors, Antigen, T-Cell/genetics
- Recombinant Fusion Proteins/genetics
- T-Lymphocytes/immunology